Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence 12 54 15
Erectile Dysfunction 12 54 42 15 17 71
Erectile Dysfunction Adverse Event 71
Sexual Impotence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1875
UMLS 71 C0242350 C1961100

Summaries for Impotence

MedlinePlus : 42 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Impotence, also known as erectile dysfunction, is related to priapism and hyperprolactinemia, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Impotence is PRL (Prolactin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Pathways in cancer. The drugs Selegiline and Fenofibrate have been mentioned in the context of this disorder. Affiliated tissues include prostate, endothelial and spinal cord, and related phenotype is normal.

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 598)
# Related Disease Score Top Affiliating Genes
1 priapism 31.8 PDE5A NOS3 NOS2
2 hyperprolactinemia 31.5 VIP SHBG PRL
3 nonarteritic anterior ischemic optic neuropathy 31.3 PDE5A NOS3 EDN1
4 nasopharyngitis 31.3 SEPTIN3 PDE5A CYP3A4
5 congestive heart failure 31.1 PDE5A NOS3 KNG1 EDNRA EDN1
6 angina pectoris 31.0 NOS3 KNG1 EDN1
7 prostatitis 31.0 PRL PDE5A KLK3
8 ischemia 31.0 NOS3 NOS2 NOS1 KNG1 EDN1
9 arteriosclerosis 30.9 SHBG NOS3 EDNRA EDN1
10 raynaud phenomenon 30.9 PDE5A EDN1
11 peyronie disease 30.9 PDE5A NOS2
12 varicocele 30.8 SHBG PRL NOS3 NOS2
13 pulmonary hypertension 30.8 VIP PDE5A NOS3 NOS2 EDNRA EDN1
14 diabetes mellitus 30.8 NOS3 NOS2 KNG1 EDN1 CYP3A4 SHBG
15 peripheral vascular disease 30.8 NOS3 NOS2 KNG1
16 gynecomastia 30.8 SRD5A1 SHBG PRL KLK3 CYP3A4
17 prostatic hypertrophy 30.8 SRD5A1 SHBG PDE5A KLK3
18 alopecia, androgenetic, 1 30.7 SRD5A1 SHBG
19 gastroparesis 30.7 PRL NOS1 CYP3A4
20 diabetic angiopathy 30.7 NOS3 NOS2 EDN1
21 androgenic alopecia 30.6 SRD5A1 SHBG PRL KLK3
22 orthostatic intolerance 30.6 NOS3 NOS2 EDN1
23 hypoactive sexual desire disorder 30.6 SHBG PRL PDE5A
24 body mass index quantitative trait locus 11 30.5 SHBG PRL PDE5A NOS3 NOS1 KNG1
25 hyperandrogenism 30.4 SRD5A1 SHBG PRL
26 prostatic hyperplasia, benign 30.4 SRD5A1 SHBG PDE5A KLK3
27 lipoid congenital adrenal hyperplasia 30.4 SRD5A1 SHBG PRL
28 urethral stricture 30.4 PDE5A KLK3
29 alopecia 30.4 SRD5A1 SHBG PRL EDNRA
30 psychosexual disorder 30.4 SHBG PRL PDE5A ALDH7A1
31 prostatic adenoma 30.3 SRD5A1 KLK3
32 pheochromocytoma 30.3 VIP PRL KNG1 EDNRA EDN1
33 cardiovascular system disease 30.3 SHBG PDE5A NOS3 NOS2 KNG1 EDNRA
34 lipoprotein quantitative trait locus 30.3 PDE5A NOS3 KNG1 EDN1
35 sexual disorder 30.3 SHBG SEPTIN8 SEPTIN6 SEPTIN3 PRL PDE5A
36 constipation 30.3 VIP NOS2 NOS1 CYP3A4
37 portal hypertension 30.2 NOS3 NOS2 EDNRA EDN1
38 myocardial infarction 30.2 SHBG PDE5A NOS3 NOS1 KNG1 EDN1
39 migraine with or without aura 1 30.1 VIP PRL PDE5A NOS3 NOS1 KNG1
40 hypertension, essential 29.6 VIP SHBG PRL PDE5A PDE3A NOS3
41 vasculogenic impotence 12.6
42 multiple system atrophy 1 11.6
43 autonomic nervous system disease 11.6
44 autonomic dysfunction 11.5
45 diabetic neuropathy 11.5
46 amyloidosis, hereditary, transthyretin-related 11.3
47 paroxysmal nocturnal hemoglobinuria 1 11.3
48 tabes dorsalis 11.3
49 kallmann syndrome 11.3
50 acth-secreting pituitary adenoma 11.3

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


tremor, angina pectoris, equilibration disorder, pelvic pain, symptom/complaint potency (excluding p07 p08), inability to maintain erection, unable to perform sex

MGI Mouse Phenotypes related to Impotence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.32 ALDH7A1 EDN1 EDNRA NOS1 NOS3 PDE3A

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
2
Fenofibrate Approved Phase 4 49562-28-9 3339
3
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
8
Allantoin Approved Phase 4 97-59-6 204
9
Zinc Approved, Investigational Phase 4 7440-66-6 32051
10
Magnesium oxide Approved Phase 4 1309-48-4 14792
11
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
19
Racepinephrine Approved Phase 4 329-65-7 838
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
22
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
23
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
24
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
25
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
26
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
27
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
28
Testosterone enanthate Approved Phase 4 315-37-7 9416
29
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
30
Methyltestosterone Approved Phase 4 58-18-4 6010
31
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
32
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
33 Monoamine Oxidase Inhibitors Phase 4
34 Anesthetics Phase 4
35 Antihypertensive Agents Phase 4
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
37 Chelating Agents Phase 4
38 Anticoagulants Phase 4
39 Immunosuppressive Agents Phase 4
40 Immunologic Factors Phase 4
41 Adrenergic alpha-Antagonists Phase 4
42 Yohimbe Phase 4
43 Mydriatics Phase 4
44 Calcineurin Inhibitors Phase 4
45 Lipid Regulating Agents Phase 4
46 Anticholesteremic Agents Phase 4
47 Antimetabolites Phase 4
48 Adrenergic alpha-1 Receptor Antagonists Phase 4
49 Insulin, Globin Zinc Phase 4
50 insulin Phase 4

Interventional clinical trials:

(show top 50) (show all 724)
# Name Status NCT ID Phase Drugs
1 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
2 Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction Unknown status NCT02943356 Phase 4 Tadalafil
3 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
4 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
5 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
6 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
7 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
8 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
9 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
10 Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction. Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
11 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
12 The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction Unknown status NCT00313898 Phase 4 sildenafil (viagra)
13 Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized Trial Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
14 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
15 Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil Completed NCT00159848 Phase 4
16 Open Label, Multicenter, Non Comparative Study, To Confirm The Efficacy And Tolerability Of Viagra In Subjects With Erectile Dysfunction And Arterial Hypertension Who Are Taking Antihypertensive Treatment. Completed NCT00150358 Phase 4 Sildenafil Citrate
17 Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
18 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose Completed NCT00137072 Phase 4 Viagra (Sildenafil Citrate) 100 mg
19 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy Completed NCT00422578 Phase 4 tadalafil
20 Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function Completed NCT01130532 Phase 4 Tadalafil;Placebo
21 An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00245596 Phase 4 sildenafil
22 An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing With 20 mg Tadalafil Completed NCT00382135 Phase 4 tadalafil;placebo
23 A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00159900 Phase 4 Sildenafil Citrate
24 A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction. Completed NCT00665340 Phase 4 Placebo;Levitra (Vardenafil, BAY38-9456)
25 Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction? Completed NCT00547599 Phase 4 tadalafil
26 A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
27 An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00151463 Phase 4 sildenafil citrate
28 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
29 A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction Completed NCT00249730 Phase 4 Sildenafil
30 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
31 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia. Completed NCT00663845 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
32 Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference Completed NCT00547352 Phase 4 tadalafil;sildenafil
33 A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction Completed NCT00147628 Phase 4 sildenafil citrate;placebo for sildenafil citrate
34 A Multicenter, Double-Blind Placebo Controlled, Fixed Dose Study With An Open-Label, Flexible Dose Phase To Assess The Efficacy Of Sildenafil Citrate In Providing A Better Sexual Experience Including Quality Of Erections And Satisfaction In Men With Erectile Dysfunction Completed NCT00245258 Phase 4 Sildenafil Citrate
35 A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction Completed NCT00301262 Phase 4 Viagra (Sildenafil citrate)
36 A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II Completed NCT00377793 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
37 The Use and Efficacy of Sildenafil in Diabetic Men With Erectile Dysfunction: the Impact on Endothelial Function, a Pilot Feasibility Study Completed NCT00199563 Phase 4 Viagra
38 A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction Completed NCT00547092 Phase 4 tadalafil;sildenafil
39 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study To Assess The Efficacy And Safety Of Viagra (Sildenafil Citrate) In Men With Erectile Dysfunction (ED) Who Do Not Self Identify. Completed NCT00343200 Phase 4 Placebo;Viagra (sildenafil citrate)
40 REALISE Levitra® - Real Life Safety and Efficacy of Levitra Completed NCT00663598 Phase 4 Levitra (Vardenafil, BAY38-9456)
41 A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
42 A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy Completed NCT00106392 Phase 4 Tacrolimus;Placebo
43 An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes. Completed NCT00664833 Phase 4
44 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction Completed NCT01698684 Phase 4 Placebo;Avanafil 100 mg;Avanafil 200 mg
45 Tadalafil 2.5 mg and 5 mg Once a Day Compared to Placebo in Day of Onset of Efficacy Completed NCT00833638 Phase 4 Placebo;Tadalafil
46 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction Completed NCT01768676 Phase 4 avanafil;Placebo
47 Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
48 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia Completed NCT00668135 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
49 Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction. Completed NCT00665054 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
50 Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals Completed NCT00662441 Phase 4 Levitra (Vardenafil, BAY38-9456)

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ginseng Preparation
Methyltestosterone
METHYLTESTOSTERONE PWDR
Papaverine
Papaverine Hydrochloride
yohimbine
Yohimbine hydrochloride

Genetic Tests for Impotence

Anatomical Context for Impotence

MalaCards organs/tissues related to Impotence:

40
Prostate, Endothelial, Spinal Cord, Smooth Muscle, Testes, Heart, Kidney

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 20293)
# Title Authors PMID Year
1
Re: Association of Erectile Dysfunction with Incident Atrial Fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA). 42 61
32186455 2020
2
Re: Relationship between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis. 42 61
32186450 2020
3
Acupuncture for erectile dysfunction in post-stroke patients: Study Protocol Clinical Trial (SPIRIT Compliant). 42 61
32282728 2020
4
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. 54 61
20043970 2010
5
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 54 61
20402554 2010
6
T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. 54 61
19800665 2010
7
Adaptive spaced education improves learning efficiency: a randomized controlled trial. 61 54
20022032 2010
8
Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 54 61
19907424 2010
9
Pharmacotherapy for erectile dysfunction. 61 54
20092451 2010
10
Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. 61 54
19686427 2009
11
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. 54 61
19884625 2009
12
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. 61 54
20112748 2009
13
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. 54 61
19701217 2009
14
Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? 61 54
19234311 2009
15
Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. 54 61
19466514 2009
16
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 61 54
19377497 2009
17
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 61 54
19387454 2009
18
Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. 61 54
19210710 2009
19
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. 54 61
19036180 2009
20
[Psychosis and sexuality]. 61 54
19365914 2009
21
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. 54 61
19143914 2009
22
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. 54 61
19138360 2009
23
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. 61 54
19010346 2009
24
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 61 54
19125990 2009
25
[Tadalafil for erectile dysfunction: excellent safety and tolerance]. 54 61
19288756 2009
26
PDE5 inhibitors in non-urological conditions. 61 54
19860698 2009
27
Online spaced education to teach urology to medical students: a multi-institutional randomized trial. 61 54
18614145 2009
28
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. 61 54
19170852 2009
29
New treatments for localized prostate cancer. 54 61
19095127 2008
30
The role of combination medical therapy in benign prostatic hyperplasia. 54 61
19002123 2008
31
5-alpha reductase inhibitors and erectile dysfunction: the connection. 61 54
19090946 2008
32
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. 54 61
18976905 2008
33
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. 54 61
18528398 2008
34
Pulmonary embolism after tadalafil ingestion. 54 61
18548330 2008
35
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. 54 61
18331258 2008
36
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. 54 61
18998474 2008
37
Potent inhibition of human phosphodiesterase-5 by icariin derivatives. 54 61
18778098 2008
38
The effect of 5 alpha-reductase inhibitors on erectile function. 61 54
18421068 2008
39
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. 61 54
18674473 2008
40
Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. 61 54
18644193 2008
41
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. 61 54
18395326 2008
42
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 61 54
18281145 2008
43
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 61 54
18423715 2008
44
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]. 54 61
18572866 2008
45
[Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction]. 54 61
18572862 2008
46
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. 54 61
18385912 2008
47
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. 61 54
18304285 2008
48
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. 61 54
18075506 2008
49
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. 54 61
18086159 2008
50
Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. 61 54
18082643 2008

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 PDE5A PDE3A NOS3 NOS2 NOS1 KNG1
2 12.71 NOS2 KNG1 KLK3 EDNRA EDN1
3
Show member pathways
12.38 PDE5A PDE3A NOS3 KNG1 KCNMA1 EDNRA
4
Show member pathways
12.35 NOS3 KCNMA1 EDNRA EDN1
5 12.2 VIP PDE3A EDNRA EDN1
6
Show member pathways
12.15 NOS3 NOS2 NOS1 EDNRA
7
Show member pathways
12.08 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
8 11.81 NOS3 NOS2 EDN1
9 11.62 SEPTIN8 SEPTIN6 SEPTIN3
10 11.57 PDE3A KCNMA1 EDNRA EDN1
11
Show member pathways
11.48 NOS3 NOS2 NOS1
12
Show member pathways
11.31 NOS3 NOS2 NOS1 ARG2 ALDH7A1
13
Show member pathways
11.3 NOS3 NOS2 NOS1
14 11.22 NOS3 EDNRA EDN1
15 11.15 PRL EDNRA EDN1
16 11.1 NOS3 NOS2 NOS1
17 11.01 NOS3 NOS2 NOS1
18
Show member pathways
10.97 NOS3 NOS2 NOS1 ARG2
19
Show member pathways
10.72 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
20 10.45 NOS3 NOS2 NOS1
21 10.37 PDE5A NOS3 NOS2 NOS1

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.87 NOS3 NOS2 NOS1 KNG1 KCNMA1 EDNRA
2 caveola GO:0005901 9.54 NOS3 NOS1 KCNMA1
3 vesicle membrane GO:0012506 9.43 NOS3 NOS2 NOS1
4 cell division site GO:0032153 9.33 SEPTIN8 SEPTIN6 SEPTIN3
5 septin complex GO:0031105 9.13 SEPTIN8 SEPTIN6 SEPTIN3
6 septin ring GO:0005940 8.8 SEPTIN8 SEPTIN6 SEPTIN3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 10.03 SRD5A1 NOS3 NOS2 NOS1 CYP3A4 ALDH7A1
2 response to lipopolysaccharide GO:0032496 9.81 NOS3 NOS2 NOS1 EDN1
3 cell redox homeostasis GO:0045454 9.79 NOS3 NOS2 NOS1
4 cellular protein localization GO:0034613 9.76 SEPTIN8 SEPTIN6 SEPTIN3
5 regulation of blood pressure GO:0008217 9.74 NOS3 EDNRA EDN1
6 response to hypoxia GO:0001666 9.72 NOS2 NOS1 KCNMA1 EDNRA EDN1
7 response to hormone GO:0009725 9.71 NOS3 NOS2 NOS1
8 negative regulation of blood pressure GO:0045776 9.65 NOS3 NOS2 NOS1
9 striated muscle contraction GO:0006941 9.64 NOS1 ARG2
10 vasoconstriction GO:0042310 9.63 EDNRA EDN1
11 androgen metabolic process GO:0008209 9.63 SRD5A1 CYP3A4
12 negative regulation of calcium ion transport GO:0051926 9.62 NOS3 NOS1
13 negative regulation of blood coagulation GO:0030195 9.62 KNG1 EDN1
14 artery smooth muscle contraction GO:0014824 9.61 EDNRA EDN1
15 cytoskeleton-dependent cytokinesis GO:0061640 9.61 SEPTIN8 SEPTIN6 SEPTIN3
16 regulation of glucose transmembrane transport GO:0010827 9.6 EDNRA EDN1
17 body fluid secretion GO:0007589 9.59 VIP EDN1
18 negative regulation of hydrolase activity GO:0051346 9.58 NOS3 NOS1
19 vasodilation GO:0042311 9.58 NOS3 NOS1 KNG1
20 endothelin receptor signaling pathway GO:0086100 9.55 EDNRA EDN1
21 nitric oxide mediated signal transduction GO:0007263 9.54 NOS3 NOS2 NOS1
22 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.52 NOS3 EDN1
23 peptidyl-cysteine S-nitrosylation GO:0018119 9.49 NOS2 NOS1
24 positive regulation of oocyte development GO:0060282 9.46 PDE5A PDE3A
25 positive regulation of guanylate cyclase activity GO:0031284 9.43 NOS3 NOS2 NOS1
26 negative regulation of potassium ion transport GO:0043267 9.33 VIP NOS3 NOS1
27 arginine catabolic process GO:0006527 9.13 NOS3 NOS2 NOS1
28 nitric oxide biosynthetic process GO:0006809 8.92 NOS3 NOS2 NOS1 ARG2

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.45 VIP SHBG SEPTIN8 SEPTIN6 SEPTIN3 PRL
2 oxidoreductase activity GO:0016491 9.93 SRD5A1 NOS3 NOS2 NOS1 CYP3A4 ALDH7A1
3 heme binding GO:0020037 9.73 NOS3 NOS2 NOS1 CYP3A4
4 hormone activity GO:0005179 9.71 VIP PRL EDN1
5 molecular adaptor activity GO:0060090 9.7 SEPTIN8 SEPTIN6 SEPTIN3
6 flavin adenine dinucleotide binding GO:0050660 9.69 NOS3 NOS2 NOS1
7 NADP binding GO:0050661 9.58 NOS3 NOS2 NOS1
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0016709 9.54 NOS3 NOS2 NOS1
9 FMN binding GO:0010181 9.5 NOS3 NOS2 NOS1
10 cadmium ion binding GO:0046870 9.48 NOS3 NOS1
11 arginine binding GO:0034618 9.43 NOS3 NOS2 NOS1
12 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS3 NOS2 NOS1
13 tetrahydrobiopterin binding GO:0034617 9.13 NOS3 NOS2 NOS1
14 nitric-oxide synthase activity GO:0004517 8.8 NOS3 NOS2 NOS1

Sources for Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....